IND Swift has informed that as per the Company’s Code of Conduct for prevention of Insider Trading read with Regulation 4 of the Schedule B of SEBI (Prohibition of Insider Trading) Regulations, 2015, and notification no. NSE/CML/2019/11 and LIST/COMP/01/2019-20 issued respectively by NSE and BSE on 2nd April, 2019, further read with SEBI circular no. SEBI/HO/ISD/ISD-SEC-4/P/CIR/2022/107 dated 05.08.2023, the Trading Window of the Company is closed for all Promoters, members of the Promoter Group, Directors, KMPs, designated person(s), connected person(s)/insiders and their immediate relatives as covered under the Code, for dealing in securities of the Company, with effect from 1st October, 2024 and will remain closed till 48 hours after the declaration of Unaudited Financial Results for the Quarter ending September 30, 2024.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: